Related Experiment Videos
[A study on the anti-metastatic effects of CD3Ak cells in nude mice]
Objective:
To investigate whether cancer draining lymph node lymphocytes activated by CD3 McAB in vitro have anti-tumor effects in vivo.
Methods:
Nude mice with highly metastatic human ovarian cancer were treated with CD3 McAB activated killer cells (CD3AK) from human ovarian cancer draining lymph node lymphocytes. 31 experimental nude mice were divided into 4 groups; the cisplatin group (7 mice), the CD3AK cells group (7 mice), the combined treatment group (7 mice), and control group (10 mice). Treatment began on the 10th day after tumor transplantation for a total of 80 days.
Results:
The transplanted tumors disappeared in 1 mouse of CD3AK group, significant difference in the anti-metastatic effect was found between the CD3AK group (2/7 mice with metastasis) and the control group (8/10 mice with metastasis). Significant difference in average tumor volume was found between the CD3AK group (0.5788 +/- 0.2549) and the control group (1.5685 +/- 0.283). The tumor growth inhibition rate reached 63.1% in the CD3AK group. Significant difference in the serum level of progesterone was found between the CD3AK group (3.3843 +/- 0.5314) and the control group (6.3480 +/- 0.7615). Significant difference in the histiocyte increase in the lymph node sinuses was found between the CD3AK group (59/69) and the control group (55/94).
Conclusion:
These results suggest that CD3AK cells appear to be effective in tumor growth inhibition, anti-metastasis and enhancing host immunologic function.
Insights
Activated killer cells derived from ovarian cancer lymph nodes show significant anti-tumor effects. These CD3AK cells demonstrated tumor growth inhibition and anti-metastatic properties in vivo.
Area of Science:
- Immunology
- Oncology
- Cell Therapy
Background:
- Metastatic ovarian cancer remains a significant clinical challenge.
- Developing novel immunotherapies is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the in vivo anti-tumor efficacy of lymphocytes activated by CD3 monoclonal antibody (McAB) from cancer-draining lymph nodes.
- To assess the potential of CD3AK cells as a therapeutic strategy against ovarian cancer.
Main Methods:
- Nude mice with human ovarian cancer were treated with CD3 McAB-activated killer cells (CD3AK).
- Mice were divided into CD3AK, cisplatin, combination, and control groups for 80 days.
- Tumor volume, metastasis, serum progesterone, and lymph node histiocytes were analyzed.
Main Results:
- CD3AK cells led to complete tumor disappearance in one mouse and reduced metastasis in 2/7 mice compared to controls (8/10).
- Average tumor volume was significantly reduced (0.5788 vs 1.5685) with a 63.1% growth inhibition rate.
- Enhanced host immune response was indicated by altered serum progesterone levels and increased lymph node histiocytes.
Conclusions:
- CD3AK cells exhibit promising anti-tumor activity, including tumor growth inhibition and anti-metastasis.
- These findings suggest CD3AK cells can enhance host immunologic function against ovarian cancer.
- CD3AK cells represent a potential cell-based immunotherapy for ovarian cancer.